SEC Filing Summary: ChromaDex Corporation (10-K)
Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Input metadata referenced "Niagen Bioscience," but the filing text identifies the registrant as ChromaDex Corporation).
Reporting Period: Fiscal year ended January 1, 2011.
Business Overview: ChromaDex supplies phytochemical reference standards, reference materials, and contract services for the dietary supplement, nutraceutical, food, beverage, pharmaceutical, and cosmetic markets. The company operates through subsidiaries ChromaDex, Inc. and ChromaDex Analytics, Inc., with headquarters in Irvine, California, and a laboratory facility in Boulder, Colorado. The company is a "Smaller Reporting Company" and its stock trades on the OTC Bulletin Board under the symbol CDXC.OB.
Key Financial Metrics
| Metric | 2010 (Ended Jan 1, 2011) | 2009 (Ended Jan 2, 2010) |
|---|---|---|
| Net Sales | $7,566,370 | $5,777,865 |
| Gross Profit | $2,944,845 | $2,041,430 |
| Gross Margin | 38.9% | 35.3% |
| Net Loss | $(2,051,676) | $(907,568) |
| Loss Per Share (Basic & Diluted) | $(0.04) | $(0.03) |
| Cash and Equivalents (Ending) | $2,226,459 | $471,378 |
| Accumulated Deficit | $(10,159,202) | $(8,107,526) |
| Capital Lease Obligations | $276,648 (Total PV) | $74,298 (Total PV) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 31% to $7.57 million, driven by increased demand for existing products and the introduction of bulk dietary supplement grade and food grade raw materials.
- Expense Increases: General and Administrative (G&A) expenses surged 84% to $3.88 million. This was primarily due to a 513% increase in share-based compensation ($1.26 million vs. $0.21 million) resulting from stock options granted following the May 2010 Private Placement, as well as costs associated with investor relations and public reporting compliance.
- Net Loss Expansion: The net loss more than doubled to $2.05 million, largely attributable to the non-cash share-based compensation expense and increased operating costs.
- Liquidity Improvement: Cash balances increased significantly from $471,378 to $2.23 million, fueled by a private placement offering in May 2010 that raised approximately $3.49 million in net proceeds, plus $1.19 million from warrant exercises.
Guidance, Outlook, and Risks
Outlook and Strategy: Management believes current capital resources are sufficient to fund operations through December 2011. The company plans to expand service capacity, implement quality accreditation programs, and grow its chemical library. Future growth is anticipated from FDA Good Manufacturing Practice (GMP) regulations in the dietary supplement industry and the expansion of bulk raw material sales, though the latter may lower gross margins.
Risks and Contingencies:
- Capital Requirements: The company has a history of operating losses and an accumulated deficit of over $10 million. It may require additional financing after December 2011, which may not be available on favorable terms.
- Regulatory Dependence: Business success is tied to FDA enforcement of GMPs for dietary supplements. Reduced enforcement could decrease demand for ChromaDex's quality control products.
- Stock Volatility: The stock is subject to "penny stock" rules and has minimal public trading volume, which may limit liquidity for investors.
- Intellectual Property: The company relies on patents and licenses (e.g., Bioluminex, Simmondsin) that may be challenged or may not result in commercial products.
Key Facts for Investor Verification
- Share-Based Compensation Impact: Verify the sustainability of profitability given that $1.26 million of the 2010 loss was non-cash share-based compensation, which is expected to continue over the next three years.
- Warrant Exercise Potential: As of Jan 1, 2011, there were 22.3 million warrants outstanding (weighted avg. exercise price $0.43). Full exercise could raise an additional $4.3 million but would cause significant dilution.
- Related Party Transactions: The company paid $1.18 million in 2010 to two officers for unpaid compensation from prior years, which was a significant cash outflow.
- Product Mix Shift: Confirm the margin impact of the new "bulk dietary supplement grade" raw materials, which have higher raw material costs and may compress gross margins as sales volume increases.
- Regulatory Catalyst: Monitor FDA enforcement actions regarding dietary supplement GMPs, as this is a primary driver for the company's core reference standards business.